Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Autor: Lee LYW; Department of Oncology, University of Oxford, Oxford, United Kingdom.; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom., Tilby M; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Starkey T; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom., Ionescu MC; UK Health Security Agency, London, United Kingdom., Burnett A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom., Hattersley R; Torbay and South Devon NHS Foundation Trust, Torquay, United Kingdom., Khan S; University of Leicester, Leicester, United Kingdom., Little M; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Liu JKH; University of Leeds, Leeds, West Yorkshire, United Kingdom., Platt JR; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom., Tripathy A; Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom., Watts I; Royal Free Hospital, London, United Kingdom., Williams ST; University of Sheffield, Sheffield, United Kingdom., Appanna N; University of Oxford, Oxford, United Kingdom., Al-Hajji Y; Birmingham Medical School, University of Birmingham, Birmingham, United Kingdom., Barnard M; UK Health Security Agency, London, United Kingdom., Benny L; UK Health Security Agency, London, United Kingdom., Buckley A; UK Health Security Agency, London, United Kingdom., Cattell E; NHS England, Leeds, United Kingdom., Cheng V; University of Leeds, Leeds, West Yorkshire, United Kingdom., Clark J; Imperial College London, London, United Kingdom., Eastlake L; Royal Cornwall Hospitals Trust, Truro, United Kingdom., Gerrand K; UK Health Security Agency, London, United Kingdom., Ghafoor Q; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Grumett S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Harper-Wynne C; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent, United Kingdom., Kahn R; Blood Cancer UK, Edinburgh, United Kingdom., Lee AJX; University College London, London, United Kingdom., Lydon A; Torbay and South Devon NHS Trust, Torquay, United Kingdom., McKenzie H; University Hospital Southampton, Southampton, United Kingdom., Panneerselvam H; Wye Valley NHS Foundation Trust, Herefordshire, United Kingdom., Pascoe J; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Patel G; Kent Oncology Centre, Maidstone, United Kingdom., Patel V; NHS England, Leeds, United Kingdom., Potter V; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom., Randle A; Royal College of Physicians, London, United Kingdom., Rigg AS; Guy's and St Thomas' Hospitals NHS Trust, London, United Kingdom., Robinson T; University of Bristol, Bristol, United Kingdom., Roylance R; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Roques T; Norfolk and Norwich University Hospitals NHS Foundation Trust, Norfolk, United Kingdom., Rozmanowski S; UK Health Security Agency, London, United Kingdom., Roux RL; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Shah K; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Sintler M; Sandwell and West Birmingham Hospitals NHS Trust, United Kingdom., Taylor H; Oxford Medical School, University of Oxford, Oxford, United Kingdom., Tillett T; Royal United Hospitals Bath, Bath, United Kingdom., Tuthill M; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Williams S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom., Beggs A; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom., Iveson T; Department of Oncology, Southampton University Hospitals, Southampton, United Kingdom., Lee SM; UCLH/CRUK Lung Cancer Centre of Excellence, London, United Kingdom., Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Middleton M; Department of Oncology, University of Oxford, Oxford, United Kingdom., Protheroe AS; Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom., Fittall MW; Royal Marsden NHS Foundation Trust, United Kingdom., Fowler T; William Harvey Research Institute, London, United Kingdom., Johnson P; University of Southampton, United Kingdom.

Publikováno v: JAMA oncology [JAMA Oncol] 2023 Feb 01; Vol. 9 (2), pp. 188-196.

Systemic treatment of colorectal cancer

Autor: Tebbutt, N.C, Cattell, E, Midgley, R, Cunningham, D, Kerr, D

Publikováno v: In European Journal of Cancer May 2002 38(7):1000-1015

Bacterial co-infections in cancer patients with COVID-19: predictors and antimicrobial resistance trends.

Autor: Abdel-Hamid, Rasha M.¹ rasha.elgyar@nci.cu.edu.eg, Bayoumi, Ahmed^2,3, Abdellateif, Mona S.⁴, Nooh, Hend A.¹, Refaat, Lobna¹, Kandeel, Eman Z.¹, Hassan, Safaa S.¹

Publikováno v: Journal of Infection in Developing Countries. Aug2024, Vol. 18 Issue 8, p1185-1195. 13p.

Cell cycle regulatory proteins as therapeutic targets: A validated method for pharmacodynamic evaluation of clinical trials

Autor: Bradbury, P, Norbury, C, Olsen, A, Slade, M, Cattell, E, Talbot, D

Publikováno v: BRITISH JOURNAL OF CANCER British Cancer Research Meeting 2004. 91

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::17122c5e699844bb552e76f9c7465ab9
http://ora.ox.ac.uk/objects/uuid:59f66919-8112-4ae4-9bed-0f90add31aab